Publicacións en colaboración con investigadores/as de Centro de Regulación Genómica (15)

2024

  1. Relationship between sex, APOE genotype, endocannabinoids and cognitive change in older adults with metabolic syndrome during a 3-year Mediterranean diet intervention

    Nutrition Journal, Vol. 23, Núm. 1

2020

  1. A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome

    Clinical Nutrition, Vol. 39, Núm. 2, pp. 378-387

2017

  1. Anomalous White Matter Structure and the Effect of Age in Down Syndrome Patients

    Journal of Alzheimer's Disease, Vol. 57, Núm. 1, pp. 61-70

  2. Potential role of (-)-epigallocatechin-3-gallate (EGCG) in the secondary prevention of Alzheimer disease

    Current Drug Targets, Vol. 18, Núm. 2, pp. 174-195

2016

  1. Orexin and sleep quality in anorexia nervosa: Clinical relevance and influence on treatment outcome

    Psychoneuroendocrinology, Vol. 65, pp. 102-108

  2. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): A double-blind, randomised, placebo-controlled, phase 2 trial

    The Lancet Neurology, Vol. 15, Núm. 8, pp. 801-810

  3. Smell–taste dysfunctions in extreme weight/eating conditions: analysis of hormonal and psychological interactions

    Endocrine, Vol. 51, Núm. 2, pp. 256-267

2015

  1. A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials

    Frontiers in Psychology, Vol. 6, Núm. JUN

  2. Circulating betatrophin levels are increased in anorexia and decreased in morbidly obese women

    Journal of Clinical Endocrinology and Metabolism, Vol. 100, Núm. 9, pp. E1188-E1196

  3. Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases

    Molecules, Vol. 20, Núm. 3, pp. 4655-4680

2014

  1. Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index

    International Journal of Endocrinology, Vol. 2014

  2. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans

    Molecular Nutrition and Food Research, Vol. 58, Núm. 2, pp. 278-288

2013

  1. Serotonin and interleukin-6: The role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms

    Psychoneuroendocrinology, Vol. 38, Núm. 9, pp. 1803-1813

  2. Targeting the endocannabinoid system in the treatment of fragile X syndrome

    Nature Medicine, Vol. 19, Núm. 5, pp. 603-607

2012

  1. Therapeutic approaches in the improvement of cognitive performance in Down syndrome: Past, present, and future.

    Progress in Brain Research (Elsevier B.V.), pp. 1-14